CARAVAGGIO
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Patient / Population Intervention / Exposure Comparison Outcome
In 1,170 patients with cancer-associated venous thromboembolism, apixaban was non-inferior to dalteparin for recurrent VTE, without excess major bleeding.
N
1,170
Design
Open-label, non-inferiority RCT
Endpoint
Recurrent venous thromboembolism
Relevance
2
Result5.6 % vs 7.9 % (HR 0.63); no excess gastrointestinal bleeding.
Agnelli G, et al. N Engl J Med. 2020;382(17):1599-1607. 10.1056/NEJMoa1915103
Discussion & critique
Unlike edoxaban (Hokusai-Cancer), apixaban showed no GI-bleeding signal — it is a preferred oral option in cancer-associated VTE, including gastrointestinal tumours.